LOVELAND, Colo., Dec. 14, 2011 /PRNewswire/ -- Heska
Corporation (NASDAQ:HSKA; "Heska"), a leading provider of advanced
diagnostic and specialty products to veterinarians, announced today
the intent to collaborate with Entegrion Inc., a company with core
expertise in blood-related disorders. The parties are to
explore unique technologies in the areas of coagulation and blood
cell-based therapeutics, for use in the veterinary market.
"Heska is pleased to announce this strategic initiative into an
exciting frontier in medicine, and expand our product and service
offerings," commented Michael
McGinley, President and Chief Operating Officer of
Heska. "As part of Heska's stated commitment to growth,
focused on the introduction of innovative and competitively
differentiated products, we seek to work with innovative leaders in
the life science sector. Entegrion is just such an innovator,
sharing a parallel path with us in advancing healthcare – Heska
committed to advancing animal health, and Entegrion committed to
identifying and developing new technologies for human medical
needs. We expect this collaboration will lead to the development of
products that advance our mutual goals."
Joseph DaCorta, Vice President
and Chief Technology Officer for Entegrion Inc., stated "Entegrion
is pleased to join forces with Heska, a veterinary industry leader,
dedicated to perfecting and supporting quality pet care and whose
pursuit of innovation directly matches Entegrion's values and focus
on meeting unmet health needs."
About Heska
Heska Corporation (NASDAQ: HSKA) sells advanced veterinary
diagnostic and other specialty veterinary products. Heska's
state-of-the-art offerings to its customers include diagnostic and
monitoring instruments and supplies as well as single use,
point-of-care tests, vaccines and pharmaceuticals. The
company's core focus is on the canine and feline markets where it
strives to provide high value products and unparalleled customer
support to veterinarians. For further information on Heska
and its products, visit the company's website at www.heska.com.
About Entegrion
Entegrion is a life sciences development company that is focused
on improving the safety and availability of the world's blood
supply. Based in North
Carolina's Research Triangle
Park, Entegrion offers patented technologies designed to
overcome limitations in storage, safety, and availability of
blood-derived products while preserving their functionality.
Many of Entegrion's advances in biologics are based on close
collaborations with leading medical research institutions.
Visit http://www.entegrion.com for more information.
Forward-Looking Statements
This announcement contains forward-looking statements
regarding Heska's future financial and operating results.
These statements are based on current expectations and are subject
to a number of risks and uncertainties including risks related to
Heska's reliance on a third party, Entegrion Inc., to collaborate
and deliver specific products of interest. There are
uncertainties regarding Heska and Entegrion's ability to
successfully commercialize new products; uncertainties regarding
Heska's ability to market, sell and distribute products;
uncertainties regarding the performance of any new products in
field use; uncertainties regarding the outcome of any
collaborations between Heska and any third party, including
Entegrion; risks related to relying on the reputation of Heska,
Entegrion or any other entity, which is subject to interpretation
and may change over time; uncertainties related to the future
development efforts of any third party; competition; and the
risks set forth in Heska's filings and future filings with the
Securities and Exchange Commission, including those set forth in
Heska's Annual Report on Form 10-Q for the quarter ended
September 30, 2011.
SOURCE Heska Corporation